Rainer Haag is a Professor at the Department of Chemistry, Freie Universität Berlin, leading the Haag Group in the Institute of Chemistry and Biochemistry. His research focuses on biodegradable and sustainable materials, dynamic hydrogels, and polymeric nanosystems for biomedical applications. Department of Chemistry, Freie Universität Berlin Member of SFB 1449: Dynamic Hydrogels at Biointerfaces Collaborator in the StemGel startup project Co-founder of CSR|Berlin interdisciplinary research institute Research Interests: Development of stimuli-responsive polymers, multivalent virus inhibitors, and functional biointerfaces. Key projects include: Antiviral coatings using heteromultivalent polymers Thermoresponsive hydrogels for stem cell expansion Graphene derivatives for bacterial capture and disinfection Lignin upcycling for sustainable resin materials Supramolecular nanosystems for drug delivery Publication Trends highlight interdisciplinary work in polymer chemistry, nanotechnology, and biomedical applications. Recent articles focus on: 2D polyglycerols for virus interactions Redox-responsive nanogels Mucus-inspired adhesive hydrogels Tumor-targeting micelles Bacterial disinfection using graphene composites Labs & Collaborations include the Polymeric and Supramolecular Nanosystems subgroup, the Dynamic Hydrogels and Biointerfaces team, and partnerships with MIT in developing bioinspired adhesives. His group contributes to DFG-funded SFB 1449 and CSR|Berlin initiatives.
Professor Matthias Mann is a world-leading scientist serving as Director of the Proteomics and Signal Transduction department at the Max Planck Institute of Biochemistry in Martinsried, Germany, and Director of the Proteomics department at the Novo Nordisk Foundation Center for Protein Research, Faculty of Health Sciences, University of Copenhagen, Denmark. With an h-index exceeding 277 and over 350,000 citations, he is recognized as the highest cited German researcher and one of the most influential scientists globally in proteomics. His educational background includes: Ph.D. in Chemical Engineering from Yale University (1988) Master's Degree in Physics from Georg August University Göttingen (1984) Bachelor's of Arts in Mathematics from Georg August University Göttingen (1982) Professor Mann's research focuses on advancing mass spectrometry-based proteomics to understand biological systems at the protein level. His work spans technological developments in mass spectrometry, bioinformatics and computational analysis, signal transduction and posttranslational modifications, and clinical proteomics applications for disease diagnosis and treatment. The Mann lab has pioneered groundbreaking methods like SILAC for quantitative proteomics and MaxQuant for proteome data analysis. Their vision is to translate proteomics knowledge into clinical practice for predictive, diagnostic, and preventive medicine, with recent work focusing on AI-guided platforms for analyzing proteomes from minimal tissue samples. Analysis of Professor Mann's recent publications reveals a strong trend toward clinical applications of proteomics, particularly in cancer research, metabolic diseases, and neurodegenerative disorders. His work increasingly integrates spatial proteomics, single-cell resolution techniques, and artificial intelligence approaches to uncover disease mechanisms and identify potential biomarkers, with a clear shift from basic technology development toward direct clinical applications and personalized medicine. Professor Mann has received numerous prestigious awards throughout his career: 2025: Elected member of the American National Academy of Sciences 2024: Dr. H.P. Heineken Award for Biochemistry and Biophysics 2023: Otto Warburg Medal 2019: Nominated member of the Bavarian Academy of Sciences 2013: Elected member of Leopoldina German National Academy of Sciences 2012: Körber European Science Award, Louis-Jeantet Foundation Prize for Medicine, Ernst Schering Prize, and Leibniz Prize Professor Mann leads a highly collaborative research team involved in multiple international networks including the Bill & Melinda Gates Foundation, Michael J. Fox Foundation for Parkinson's Research, CLINSPECT-M, and Munich Heart Alliance. His lab has mentored numerous successful researchers, with several former postdocs receiving prestigious ERC Starting Grants. The Mann group has developed innovative clinical proteomics pipelines for analyzing archived tissue specimens and body fluids, aiming to identify protein markers for early detection of diseases such as diabetes and cancer. The Mann lab operates across two major research centers with state-of-the-art mass spectrometry facilities. Their Clinical Knowledge Graph platform integrates multi-omics data with extensive metadata, creating an ecosystem for machine learning applications in proteomics. Current research focuses on developing highly sensitive methods that can profile thousands of proteins from minimal cell samples, enabling the identification of critical disease-related proteins and supporting the development of individualized therapies.
Prof. Ralph Hückelhoven is a Professor of Phytopathology at the Technical University of Munich (TUM), affiliated with the TUM School of Life Sciences. His research focuses on the molecular and biological mechanisms underlying plant diseases, particularly plant immunity, pathogen exploitation of signal transduction, and host-pathogen interactions. He leads the Chair of Phytopathology at TUM since 2006, following academic roles at universities of Kiel and Hohenheim. Education: PhD (1999) and habilitation in molecular phytopathology (2005) from Justus Liebig University Giessen, after a biology degree at RWTH Aachen University. Awards: Julius Kühn Prize (2004) and leadership of a DFG Junior Research Group (2002-2006). His research spans plant immunity at cellular and molecular levels, including studies on receptor kinases (e.g., MIK2, LORE), RAC GTPases (e.g., RACB), and metabolomics-driven insights into pathogen resistance. He has published over 100 peer-reviewed articles, examining topics like fungal toxins, volatile signaling, and crop disease management. Key publications include work on Arabidopsis immune receptors, barley powdery mildew susceptibility factors, and Fusarium head blight resistance. Research integrates genetics, proteomics, and metabolomics to advance disease-resistant crop development. His lab investigates host-pathogen interactions across scales—from molecular signaling to field epidemiology—contributing to sustainable agricultural strategies against plant pathogens.
Prof. Friederike Ebner holds the Chair of Infection Pathogenesis at the Technical University of Munich (TUM) since 2023, within the TUM School of Life Sciences. Her research focuses on the immunobiology of parasite infections, particularly studying gastrointestinal helminths like Ascaris suum and their interactions with host immune systems to design novel intervention strategies. She also develops biomedical models for studying infectious diseases. Educational Background: Friederike Ebner earned a biotechnology degree from TU Berlin and Dongseo University (South Korea). She completed her PhD in biology at Humboldt University Berlin (2014), followed by postdoctoral research in immunology at Freie Universität Berlin, where she became an assistant professor before moving to TUM. Research Interests: Her work spans helminth-host immune dynamics, vaccine development, microbiome interactions in parasitic infections, and translational models for human diseases. Key topics include Th2/Th1 immune balance, helminth-derived immunomodulators, and xenotransplantation safety. Notable Contributions: Her recent studies address diagnostic methods for ascariasis, microbiome roles in helminth survival, and immunotherapeutic applications of parasite products. Current efforts emphasize bridging fundamental immunology with clinical and veterinary applications. Professional Activities: Prof. Ebner teaches immunology and parasite biology at TUM while maintaining active collaborations in global health and infectious disease research. She advocates for interdisciplinary approaches to address knowledge gaps in parasitology and vaccinology.
Dr. Angelika Rambold is a Group Leader at the Max Planck Institute of Immunobiology and Epigenetics in Freiburg, Germany, heading the Laboratory for Metabolic Organelle Networks in Immunology within the Department of Developmental Immunology. Previously affiliated with the University of Münster's Center for Molecular Biology of Inflammation (ZMBE) and Institute of Medical Biochemistry until January 2025, she investigates how intracellular organelle networks regulate immune cell function during inflammation, infection, and metabolic stress. Her research centers on dynamic interactions between mitochondria, lysosomes, lipid droplets, and autophagosomes during cellular adaptation to nutrient deprivation and pathogen challenge. Key interests include organelle communication mechanisms in immune cell activation, metabolic reprogramming in T cells and macrophages, and how defects in organelle networks drive primary immunodeficiencies like Chediak-Higashi syndrome. She employs advanced live-cell microscopy, super-resolution imaging, metabolomics, and single-cell transcriptomics to dissect these processes in primary immune cells and human disease models. Analysis of her publication record reveals consistent focus on mitochondrial dynamics as a central regulator of immune cell metabolism and fate determination. Landmark studies demonstrate TFEB-mediated itaconate synthesis for bacterial control in macrophages and coordinated organelle network responses during starvation, establishing critical links between organelle communication, immunometabolism, and disease pathogenesis across multiple immune cell types. Dr. Rambold serves as a supervisor in the Cells in Motion International Max Planck Research School (CiM-IMPRS) Graduate Programme, mentoring PhD students in interdisciplinary research. Her laboratory maintains active collaboration with the Center for Chronic Immunodeficiency (CCI) at the University of Freiburg to translate basic findings on organelle-mediated immune defects into clinical insights for patient-oriented research.
Prof. Dr. rer. nat. Lothar Elling is a University Professor and director at the Helmholtz Institute for Biomedical Engineering, RWTH Aachen University, Germany. His research focuses on biomaterials, glycoengineering, and enzymatic synthesis of carbohydrates and glycoconjugates. Institution: RWTH Aachen University Research Unit: Helmholtz Institute for Biomedical Engineering Academic Rank: Full Professor Prof. Elling's research interests include: Glycoengineering of biomaterials Enzymatic synthesis of glycans Glycosyltransferase immobilization Glycan-protein interactions Biocatalytic cascade reactions Biomedical applications of glycomaterials His recent publications demonstrate strong expertise in: - Automated enzymatic glycan synthesis - Multi-enzyme cascade systems for nucleotide sugar production - Glycosyltransferase engineering - Galectin-targeted glycomaterials - Microgel-based biosensors
Prof. Dr. Michael Schloter serves as Director of the Research Unit for Comparative Microbiome Analysis at Helmholtz Munich since 2011 and holds a Professorship in Microbiology at the Technical University of Munich since 2010. He concurrently acts as Principal Investigator at both the German Center for Lung Diseases (DZL) and the Central for Food and Nutrition (ZIEL) at TU Munich, driving interdisciplinary research at the intersection of environmental and human health through the "Planetary Health" framework. His educational foundation was built through diploma studies at Ludwig Maximilian University Munich and doctoral research at the University of Bayreuth, followed by formative work in Brazil and the United States where he pioneered bioinocula development for stress-resilient agriculture. At Helmholtz Munich (formerly GSF), he evolved from group leader in soil microbial ecology (2001) to Research Unit Director, expanding his focus from agricultural systems to human microbiome-health connections. Dr. Schloter's research program centers on microbiome-host crosstalk across ecological scales, investigating how environmental microbiota interact with human and plant microbiomes to influence health outcomes. His work integrates ecological theory with microbiome analysis to decode host-microbe co-evolution patterns, with applications spanning sustainable agriculture, allergy prevention, and infection control. Key thematic pillars include holobiont theory, probiotic development, and microbiome-mediated disease prevention through environmental quality improvement. Analysis of his 2025 publications reveals a strategic research portfolio bridging fundamental and applied microbiome science. Agricultural studies dominate (maize, potato, apple systems), examining microbial inoculants and soil management, while human health investigations explore preterm birth complications and Antarctic mammal microbiomes. Computational approaches for antimicrobial resistance assessment and ecosystem-scale projects like JenaTron demonstrate methodological breadth, all converging on translating microbiome functionality into real-world sustainability solutions. Major recognitions include: Election to the Bavarian Academy of Science (2021) Consistent placement among the top 1% of highly cited global researchers (2019-2021) Heinrich Baur Research Award (2011) for agricultural microbiology contributions As Research Unit Director, Schloter leads large-scale collaborative initiatives including the DZL and ZIEL consortia, securing major funding for microbiome standardization projects and international research networks. His leadership extends to developing analytical frameworks for cross-ecosystem microbiome comparisons and establishing protocols for translating microbial ecology principles into clinical and agricultural applications. The Comparative Microbiome Analysis unit operates as a nexus for multi-host microbiome research, employing comparative genomics, field-scale agricultural trials, and clinical cohort studies to investigate microbiome dynamics across environmental, plant, and human systems. Current infrastructure includes advanced sequencing facilities and experimental platforms for plant-microbe and host-microbe interaction studies under controlled and natural conditions.
Martin Kaltenpoth serves as Director at the Max Planck Institute for Chemical Ecology in Jena since 2020 and Professor for Evolutionary Ecology at Johannes Gutenberg University of Mainz since 2015. Previously, he led the Research Group Insect Symbiosis at the MPI for Chemical Ecology from 2009 to 2015. Education: PhD in Biology (summa cum laude), University of Würzburg, 2006 Diploma in Biology (with honors), University of Würzburg, 2003 His research centers on insect-bacterial symbioses , investigating evolutionary, ecological, and chemical dimensions of host-microbe interactions. Key foci include nutritional and defensive symbiosis in beetles, genomic adaptations of symbiotic bacteria, and chemical mediation of symbiotic relationships. His work bridges entomology, microbiology, and chemical ecology to unravel coevolutionary mechanisms. Analysis of recent publications reveals dominant trends in beetle-microbe systems, emphasizing symbiont roles in cuticle synthesis, antifungal defense, and host-plant adaptation. His studies frequently employ genomic, biochemical, and experimental approaches across diverse insect lineages. No scientific awards were documented in the source material. While specific advisees and grants remain unlisted, his leadership of research groups and dual academic appointments indicate active supervision of graduate researchers and externally funded projects in symbiosis evolution. Currently directing research at the Max Planck Institute, Kaltenpoth advances understanding of symbiotic systems with implications for evolutionary theory and sustainable pest management strategies.
Professor Stephan A. Sieber is a leading researcher in bioorganic chemistry at the Technical University of Munich (TUM), where he holds the Chair of Organic Chemistry II within the TUM School of Natural Sciences. His research program focuses on developing new drugs against multidrug-resistant bacteria through a multi-disciplinary approach that integrates synthetic chemistry, functional proteomics, microbiology, and protein biochemistry. His laboratory has made significant contributions to identifying unprecedented antibacterial targets beyond the scope of current antibiotics and exploiting these for chemical manipulation. Recent work has increasingly incorporated machine learning approaches to accelerate antibiotic discovery, with notable publications on AI-guided pipelines, drug-target interaction prediction, and high-throughput screening optimization. Sieber's research has resulted in the discovery of new active substances, some of which are currently being optimized for medical applications. His group's publications reveal a strong focus on chemical proteome mining, natural product mode of action studies, and novel antibacterial target identification. The lab has published extensively in top journals including Nature Chemistry, Nature Communications, and ACS Central Science. Inhoffen Medal (2024) Max Bergmann Medal (2023) ERC Advanced Grant (2023) Merck Future Insight Prize (2020) Klaus Grohe Prize (2020) ERC Consolidator Grant (2016) Professor Sieber leads an active research group that maintains a strong presence in the scientific community through regular publications, conference presentations, and collaborations. His laboratory website and BlueSky presence (@sieberlab.bsky.social) demonstrate ongoing research activities and engagement with the broader scientific community. He has successfully secured significant research funding including multiple ERC grants that have supported his innovative work in antibiotic discovery.
Professor Charlotte Kloft is Head of the Department of Clinical Pharmacy & Biochemistry at the Institute of Pharmacy, Free University of Berlin since 2011, and spokesperson for the interdisciplinary Graduate Research Training Program PharMetrX 'Pharmacometrics and Computational Disease Modelling' since 2008. She previously served as Professor and Head of the Department of Clinical Pharmacy at Martin-Luther-University Halle-Wittenberg (2005-2011) and as Scientific Assistant/Senior Assistant at Freie Universität Berlin (1999-2005). Her academic credentials include a habilitation in Clinical Pharmacy from Freie Universität Berlin (2003) and a Dr. rer. nat. (summa cum laude) from the same institution (1997). She earned her license as a pharmacist in 1992 after completing pharmacy studies at Johannes Gutenberg-University, Mainz (1987-1991). Professor Kloft's research focuses on pharmacometrics, computational disease modeling, and therapeutic drug monitoring across multiple therapeutic areas. Her work bridges pharmaceutical sciences with clinical practice, with particular emphasis on personalized dosing strategies for oncology, antimicrobial resistance, and inflammatory bowel diseases. She has pioneered research in optimizing drug dosing through pharmacokinetic/pharmacodynamic modeling, with applications in both antibiotic and cancer therapies. Her recent publications demonstrate a strong evolution toward integrating advanced computational approaches with clinical pharmacology, including machine learning applications in pharmacometrics, personalized dosing strategies for biologics during pregnancy, and developing nationwide infrastructure for therapeutic drug monitoring in cancer therapy through the ON-TARGET study. Academic Center of Excellence of Pharsight (now Certara), USA (since 2000) Habilitationsreisestipendium of Dr. August and Dr. Anni Lesmüller-Stiftung (2002) Ernst-Reuter-Preis of Ernst-Reuter-Gesellschaft (1998) Joachim-Tiburtius-Preis of Berlin Senate (1998) Young Investigator Award of EORTC-PAMM (1997) Professor Kloft has successfully supervised numerous doctoral students whose research spans diverse areas including CAR-T cell therapy, antimicrobial resistance, inflammatory bowel disease treatment optimization, and pharmacokinetic modeling of novel therapeutic agents. Her research group has secured significant funding for projects including GlobalResist, ON-TARGET, ABIMMUNE, COMBINATORIALS, and TAIN. She leads a vibrant research ecosystem at the Free University of Berlin with strong collaborations across Europe and internationally, maintaining state-of-the-art laboratory facilities including Biosafety Level 2 certified labs for infectious disease research.
Prof. Dr. Jörg Stülke is a full Professor of Microbiology and Head of the Department of General Microbiology at the Institute of Microbiology and Genetics, University of Göttingen. He has held this position since 2003 and leads an active research group focused on bacterial metabolism and gene regulation. His research spans two major model systems: the pathogenic bacterium Mycoplasma pneumoniae and the well-studied Bacillus subtilis . His group employs systems-level approaches including transcriptomics, metabolomics, and bioinformatics to understand metabolic regulation and gene expression. Key interests include protein phosphorylation, RNA-mediated regulation, mRNA processing, and the role of second messengers such as cyclic di-AMP in bacterial physiology and pathogenicity. The recent publications reveal a strong trend in molecular microbiology, functional genomics, and systems biology. His work often integrates experimental and computational methods, particularly evident in the development and maintenance of the SubtiWiki database for B. subtilis . The research bridges fundamental mechanisms of life with applications in understanding bacterial virulence and cellular homeostasis. He is affiliated with several graduate programs under the Göttingen Graduate Center for Neurosciences, Biophysics, and Molecular Biosciences (GGNB), including: Molecular Biology (IMPRS) Biomolecules: Structure - Function - Dynamics (GZMB) Molecular Biology of Cells (GZMB) Microbiology and Biochemistry Genome Science (IMPRS) While no individual students are listed, he clearly supervises doctoral candidates through these programs. His group has secured significant research output, including publications in Science , Nucleic Acids Research , and PLOS Pathogens , indicating successful grant funding and collaborative research. The lab maintains a dedicated website at http://genmibio.uni-goettingen.de/ , which serves as a hub for research activities and resources like SubtiWiki.
Prof. Dr. Ulrich Kleinekathöfer is a Full Professor of Theoretical Physics at Constructor University (formerly Jacobs University Bremen) in the School of Science. His research focuses on computational physics and biophysics, particularly on light-harvesting complexes, membrane transport, and quantum dynamics in biological systems. He leads the Computational Physics and Biophysics research group and coordinates the MSCA Doctoral Training Network "PhotoCaM". His educational background includes: PhD from Max-Planck-Institut für Strömungsforschung, Göttingen (1996) Diploma in Physics from Universität Göttingen (1993) Habilitation in Physics from Technische Universität Chemnitz (2002) Prof. Kleinekathöfer's research spans multiple areas of computational biophysics and theoretical physics. His primary interests include excitation energy transfer in light-harvesting complexes , molecular transport through membrane channels and nanopores , and quantum dynamics in open systems . His group develops and applies advanced computational methods including molecular dynamics simulations, quantum chemistry calculations, and machine learning approaches to study these phenomena. A significant portion of his work focuses on photosynthetic systems, particularly how energy is transferred and converted in natural light-harvesting complexes, with implications for renewable energy technologies. His recent publications demonstrate a strong trend toward integrating machine learning with traditional computational methods, particularly in the fields of quantum chemistry and molecular dynamics. There's a clear focus on multifidelity approaches that balance computational efficiency with accuracy. His work spans from fundamental quantum dynamics to applied research on antibiotic transport mechanisms, showing remarkable breadth while maintaining depth in computational methodology development. His notable recognition includes: Tan Chin Tuan Exchange Fellowship, NTU Singapore (2019) Prof. Kleinekathöfer has supervised numerous PhD students and postdoctoral researchers, with a current group comprising several PhD candidates and research associates. His research is supported by multiple funding sources including the Deutsche Forschungsgemeinschaft (DFG), European Union through MSCA Doctoral Network PhotoCaM, and previously through the Innovative Medicines Initiative "Translocation" and Marie Curie Training Program "Translocation". His collaborative network spans internationally, with partnerships at institutions in Germany, USA, Greece, and Switzerland. The Computational Physics and Biophysics Group operates within Constructor University's research infrastructure, utilizing high-performance computing resources for their simulations. The group maintains active collaborations with experimental groups to validate and inform their computational models, creating a strong interdisciplinary research environment focused on understanding fundamental biophysical processes at the molecular level.
Univ.-Prof. Dr. med. Martin A. Kriegel serves as full Professor and Department Head of the Department of Translational Rheumatology and Immunology at the Institute of Musculoskeletal Medicine, University of Münster, while maintaining an active laboratory at Yale School of Medicine. He leads the Section for Rheumatology and Clinical Immunology (SRKI) at Medical Clinic D, where his team integrates clinical care with cutting-edge microbiome research. His department operates from Röntgenstraße 21 and Von-Esmarch-Str. 54 in Münster, Germany, with extensive collaborations including the "Cells in Motion" research initiative and the CiM-IMPRS graduate program. Dr. Kriegel's research program focuses on the critical interface between host immunity and microbiota, particularly investigating how gut commensals translocate to host tissues and trigger autoimmune responses. His laboratory pioneered the discovery that specific pathobionts like Enterococcus gallinarum and certain Lactobacillus strains can translocate from the gut to mesenteric lymph nodes, liver, and other sites, driving autoimmune responses through molecular mimicry of human autoantigens. His work has established fundamental mechanisms by which microbiota influence rheumatic diseases, cutaneous autoimmunity, and cancer immunology, with particular emphasis on Ro60 autoantigen mimicry, TLR7-dependent pathways, and diet-microbiome interactions. The laboratory employs advanced techniques including gnotobiotic mouse models, humanized systems, and detailed molecular characterization of host-pathobiont interactions. Analysis of Dr. Kriegel's publication record reveals a consistent trajectory of high-impact research connecting microbiome dynamics to autoimmune pathogenesis. His most recent work (2023-2025) demonstrates increasingly sophisticated understanding of how specific bacterial strains influence disease phenotypes across multiple autoimmune conditions, with notable advances in identifying shared microbiome signatures across lupus and inflammatory bowel disease. The publications show progressive refinement from initial observations of microbial translocation to detailed mechanistic insights into tryptophan catabolism pathways, structural basis of molecular mimicry, and diet-sensitive microbial triggers. Dr. Kriegel's scientific recognition includes US Patent No. 11,058,756 B2 for compositions treating autoimmune diseases by reducing enterococcus, reflecting the translational potential of his research. His laboratory receives substantial funding, most notably a $3 million award from the Lupus Research Alliance for the TransLuMi project investigating gut pathobiont translocation in systemic lupus erythematosus. As an educator and mentor, Dr. Kriegel directs a substantial research team including multiple postdocs (Drs. Marcia Pereira, Nathalie Becker), PhD candidates (Anna Brinkhege, Carina Brune, Helen Fuhrmann), and laboratory specialists. He participates in the CiM-IMPRS graduate program and supervises medical students through the MedK program. His laboratory currently manages multiple significant research projects including: (A) intestinal wall permeability and pathobiont translocation in autoimmunity; (B) diet-environment-microbiome interactions; (C) microbiota disruption of immunological tolerance; and (D) microbiome roles in lymphoma development. The Kriegel laboratory maintains state-of-the-art facilities at both Münster and Yale, with specialized capabilities in gnotobiotic research, microbiome analysis, and immune profiling. His team collaborates with international partners including Dr. Eran Elinav at Weizmann Institute, Dr. Nissan Yissachar at Bar-Ilan University, Prof. George Tsokos at Harvard, and Prof. Ilana Brito at Cornell University. The laboratory's website (https://www.medizin.uni-muenster.de/mikrobiom/startseite/) details ongoing projects and research opportunities.
Dr. Lara Urban is a Principal Investigator at Helmholtz Munich and Helmholtz AI, and a TUM Junior Fellow at the Technical University of Munich's Life Sciences School. Her research integrates genomics and artificial intelligence to address One Health challenges, focusing on environmental health, biodiversity conservation, and pathogen surveillance. She holds a PhD from EMBL-EBI and the University of Cambridge (2019) and Master's degrees from Julius-Maximilians-University of Würzburg (2015). Her work leverages portable genomic technologies for real-time data analysis in clinical, environmental, and conservation contexts. Key areas include studying bioaerosols, pathogen detection, and genomic diversity in endangered species like the kākāpō. Awards include the Young Scientist of the Year 2022 and Humboldt Research Fellowship. Her team has published on nanopore sequencing applications, antibiotic resistance, and conservation genomics. Collaborations span institutions like the University of Zurich and ETH Zurich, funded by EU Horizon Europe, BMBF, and Helmholtz grants. Current initiatives include fieldwork in Chile and advancing genomic equity through democratized tools.
Matthias Feige is an Associate Professor of Cellular Protein Biochemistry at the Technical University of Munich (TUM). He leads the Focus Group for Cellular Protein Biochemistry, previously serving as a Rudolf Mößbauer Tenure Track Assistant Professor. His research focuses on understanding cellular proteome integrity, particularly in the secretory pathway, combining protein biochemistry and cell biology. Key interests include protein folding, quality control mechanisms, and their biomedical applications. Education & Career: PhD in Biochemistry (2009), TUM under Johannes Buchner Postdoctoral Fellowship at St. Jude Children’s Research Hospital (Memphis, USA) with Linda Hendershot Head of the Cellular Protein Biochemistry Lab at TUM since 2015 Research Interests: Feige’s work explores molecular mechanisms governing protein biogenesis, secretory pathway proteins, and their roles in immunity. His interdisciplinary approach targets fundamental biology and translational applications like protein engineering and therapy development. Scientific Contributions: His publications highlight advancements in cytokine assembly, ER quality control, and protein aggregation mechanisms. Notable recent work includes studies on KDELR3 signaling, helminth immune modulation, and engineered cytokines. Awards & Recognition: Leopoldina Fellowship (2011–2014) Fellow of the Daimler and Benz Foundation (2016) Rainer Rudolph Award (2012) Multiple honors from TUM and international institutions Labs & Teams: He directs a lab investigating protein biogenesis and proteostasis. Collaborations span biochemistry, immunology, and structural biology, with a focus on translational research.
